Study of TYK-01054 for advanced solid tumors
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called TYK-01054 for people with advanced solid tumors that have stopped responding to standard treatment. The drug targets a specific cell pathway (Hippo) that may help slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor that is locally advanced or has spread, and standard treatments no longer work or are not tolerated.
- You have at least one measurable tumor (can be seen on scans).
- You are generally well enough to carry out daily activities (ECOG 0-1).
- You have adequate organ function (liver, kidneys, heart, lungs, etc.).
- You have not taken a TEAD inhibitor before (a type of targeted therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This trial tests a new drug called HSK46256 for people with advanced solid tumors that have not responded to standard treatments. The drug may target cancer cells with certain genetic changes, and the study aims to find the best dose and see how well it works.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests an experimental drug called BGC515 for people with advanced solid tumors, including mesothelioma and EHE, that have not responded to standard treatments. The drug works by targeting a specific cell signaling pathway (Hippo) that may be involved in cancer growth.
This trial tests a new drug, TYK-00540, for people with solid tumors that have not responded to or cannot tolerate standard treatments. It also looks at specific types of breast and ovarian cancer.
Hear when a new Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.